CoChat

Vancomycin combined with piperacillin/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal beta-lactams: a systematic review and network meta-analysis

Pan, Kunming, Li, Ranyi, Li, Yanli, Ding, Xiaoqiang, Li, Xiaoyu, Lv, Qianzhou · 2025 · Journal of Antimicrobial Chemotherapy

The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.

Abstract

Objective: To explore whether vancomycin plus piperacillin/tazobactam actually increases nephrotoxicity compared with other anti-pseudomonal beta-lactams (BLs). Methods: PubMed, Embase, Web of Science, Cochrane, CNKI, Wanfang and VIP were searched from inception to October 2023. The primary outcomes were acute kidney injury (AKI) as defined as acute increase in serum creatinine of 0.3 mg/dL or 50% and severe Stage 2–3 AKI. Results: We included 70 studies (76 638 patients). Network meta-analysis indicated that vancomycin plus piperacillin/tazobactam was associated with significantly higher AKI risk than vancomycin plus cefepime (OR 2.55, 95% CI 2–3.28), vancomycin plus meropenem (OR 2.26, 95% CI 1.71–3.02) and vancomycin plus other uncommonly used BLs (OR 2.47, 95% CI 1.87–3.29). Also, vancomycin + piperacillin/tazobactam was associated with significantly higher Stage 2–3 AKI risk than vancomycin + cefepime (OR 2.22, 95% CI 1.34–3.62), vancomycin + meropenem (OR1.96, 95% CI 1.22–3.25) and vancomycin + uncommonly used BLs (OR 2.81, 95% CI 1.66–4.91). Vancomycin plus piperacillin/tazobactam did not result in a significant difference in the incidence of receiving dialysis treatment, mortality, length of stay and time to AKI. Subgroup analyses of studies conducting propensity score matching demonstrated vancomycin + piperacillin/tazobactam was associated with significantly higher AKI rates than vancomycin + cefepime (OR 2.19, 95% CI 1.38–3.47) and vancomycin + meropenem (OR 1.38, 95% CI. 1.18–1.60). Subgroup analysis of critically ill patients and children indicated that vancomycin + piperacillin/tazobactam was associated with significantly higher AKI rates. Conclusions: Vancomycin + piperacillin/tazobactam significantly increased the risk of AKI and severe Stage 2–3 AKI compared with vancomycin plus other BLs. More prospective studies are needed.

Overview

Integrity signals

Registry

Crossref · 10.1093/jac/dkae410

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 6

  1. Coutinho Cabral, 2021, Acute kidney injury in the concomitant treatment of vancomycin with piperacillin/tazobactam, Rev OFIL, 31, 45, 10.4321/s1699-714x20210001000011 · doi:10.4321/s1699-714x20210001000011
  2. Gao, 2015, Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized children with or without concomitant piperacillin-tazobactam, Fudan Univ J Med Sci, 42, 743, 10.3969/j.issn.1672-8467.2015.06.009 · doi:10.3969/j.issn.1672-8467.2015.06.009
  3. Wen, 2021, The effects of vancomycin monotherapy and combined beta-lactam therapy on occurrence and prognosis of acute kidney injury in patients with sepsis, Tianjin Yiyao, 49, 36, 10.11958/20201821 · doi:10.11958/20201821
  4. Xu, 2021, Acute kidney injury in critically ill patients receiving vancomycin and concomitant beta-lactam antibiotics, Zhongnan Yaoxue, 19, 2699, 10.7539/j.issn.1672-2981.2021.12.043 · doi:10.7539/j.issn.1672-2981.2021.12.043
  5. Wang, 2023, Comparison of acute kidney injury risk associated with vancomycin and concomitant piperacillin-tazobactam or carbapenem, Chin J Hosp Pharm, 43, 1851, 10.13286/j.1001-5213.2023.16.14 · doi:10.13286/j.1001-5213.2023.16.14
  6. Chu, 2023, Effect of vancomycin combined with piperacillin tazobactam on acute kidney injury in patient with sepsis, Northwest Pharm J, 38, 135, 10.3969/j.issn.1004-2407.2023.05.024 · doi:10.3969/j.issn.1004-2407.2023.05.024

Cited by

See all 22

Metadata

Authors
Pan, K., Li, R., Li, Y., Ding, X., Li, X., & Lv, Q.
Affiliations
  • Fudan University (CN)
  • Shanghai Medical College of Fudan University (CN)
Corresponding author
Pan, Kunming
Venue
Journal of Antimicrobial Chemotherapy
Published
2024-11-13
Volume
80
Issue
1
Pages
47-58
ISSN
  • 0305-7453 (ISSN-L)
  • 1460-2091
OpenAlex
W4404334750
Cited by
16
References
94
Citations by year
2026: 13 · 2025: 3
FWCI
1.04
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Antimicrobial Chemotherapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (82204520)
  • China International Medical Foundation (Z-2021-46-2101)
  • Chinese Pharmaceutical Association (CPA-Z05-ZC-2023-003)
  • Shanghai Pharmaceutical Association ((2023)04)
  • Shanghai Municipal Health Commission (202240293, shslczdzk06504)
  • Shanghai Hospital Development Center Foundation (SHDC12024632)
Topics
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
  • Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Keywords
vancomycin, piperacillin-tazobactam, acute kidney injury, nephrotoxicity, cefepime, meropenem, combination antibiotic therapy, critically ill patients, dialysis, mortality, length of hospital stay, propensity score matching, propensity score weighting
MeSH terms
Cefepime, Piperacillin, Tazobactam Drug Combination, Meropenem, Anti-Bacterial Agents, Drug Therapy, Combination, Humans, Vancomycin, beta-Lactams, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.